Original Publication Date: 24 May, 2016
Publication / Source: Lung Cancer Management
Authors: Denis L Jardim & Debora de Melo Gagliato
It is estimated that 224,390 new cases of lung cancer will be diagnosed in 2016 in USA, making it the second most incident cancer for all genders, only behind breast cancer. Additionally, lung cancer will be first cause of cancer death in USA during this year, causing 150,080 estimated deaths . Although lung cancer mortality is slowly decreasing over the last years, data indicate of lung cancer diagnosis and treatment is still an unmet need. One of the key challenges is that approximately 70% of lung cancers are diagnosed in advanced stage, for which curative treatment is not possible . The majority (85%) of lung cancers are classified as NSCLC, while the reaming represents small-cell lung cancers, which is associated with a dismal prognosis .
- NICE green lights Tecentriq® (atezolizumab) for most common lung cancer
- Approval granted for novel non-small cell lung cancer drug, Imfinzi®
- Nivolumab, ipilimumab combo succeeds in Phase III lung cancer trial
The standard treatment for advanced NSCLC over the last decade is chemotherapy, including platinum-based doublets. These regimens are associated with a response rate (RR) of approximately 20%, and median overall survival (OS) under 12 months . For selected patients, after four to six cycles of platinum-doublets regimens, maintenance therapy either with chemotherapy or EGFR inhibitors is associated with a modest improvement in OS . One of the greatest advances obtained over the last decade for the management of advanced NSCLC is the consolidation of a molecular-based approach. Approximately 70% of NSCLC are nonsquamous, and 40% of them may present with a targetable genetic alteration. Tyrosine kinase inhibitors are available for patients whose tumors harbor EGFR mutations, ALK translocations and, more recently, ROS1 fusions. A matched targeted therapy is associated with an RR of 60–70%, and disease control that frequently surpasses 12 months . Nonetheless, these therapies are not curative; treatment resistance development is almost a rule. In addition, there are no molecularly oriented therapies approved for advanced lung cancers with squamous cell histology. Second-line options for advanced NSCLC were restricted to docetaxel and pemetrexed.